Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of L-Name. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 2/20 | 0.38 |
| ▸ | OTC | P00480 | 1/20 | 0.37 |
| ▸ | DDAH1 | O94760 | 2/20 | 0.36 |
| ▸ | F2 | P00734 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | S1PR2 | O95136 | 2/20 | 0.32 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.32 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.32 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.32 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.32 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.30 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| L-Name SCHEMBL29362113 | 0.95 | NOS1 (0.41) | NOS1OTCDDAH1F2ALDH1A1 | |
| L-Name SCHEMBL5966636 | 0.95 | NOS1 (0.41) | NOS1OTCDDAH1F2ALDH1A1 | |
| Nitroarginine SCHEMBL6054201 | 0.86 | OTC (0.52) | NOS1OTCDDAH1TSHR | |
| SCHEMBL14350781 | 0.83 | NOS1 (0.40) | NOS1OTCDDAH1F2DPP7 | |
| SCHEMBL12556165 | 0.82 | MEN1 (0.39) | NOS1DDAH1F2DPP7ADAM17 | |
| SCHEMBL12556286 | 0.82 | MEN1 (0.39) | NOS1DDAH1F2DPP7ADAM17 | |
| SCHEMBL7369016 | 0.81 | F2 (0.35) | NOS1DDAH1F2ADAM17TSHR | |
| Phosphoric Acid SCHEMBL7161899 | 0.80 | EPHX1 (0.42) | DDAH1F2S1PR2S1PR1S1PR3 | |
| Nitroarginine SCHEMBL8527873 | 0.80 | DDAH1 (0.53) | NOS1OTCDDAH1TSHR | |
| Nitroarginine SCHEMBL14220319 | 0.80 | DDAH1 (0.53) | NOS1OTCDDAH1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7105501-B2 | Salt compositions for inhibition of the formation of new vaculature by angiogenesis | ANGIOGENE PHARMACEUTICALS LTD. (GB) | 2006-09-12 | — | — | US | claimed |
| EP-1311514-B1 | COMPOSITIONS WITH VASCULAR DAMAGING ACTIVITY | ANGIOGENE PHARM LTD (GB) | 2005-01-26 | — | — | EP | claimed |
| US-7105501-B2 | Salt compositions for inhibition of the formation of new vaculature by angiogenesis | ANGIOGENE PHARMACEUTICALS LTD. (GB) | 2006-09-12 | — | — | US | disclosed |
| EP-1311514-B1 | COMPOSITIONS WITH VASCULAR DAMAGING ACTIVITY | ANGIOGENE PHARM LTD (GB) | 2005-01-26 | — | — | EP | disclosed |
| US-20030181424-A1 | Compositions with vascular damaging activity | ANGIOGENE PHARMACEUTICALS LTD. (GB) | 2003-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030181424-A1 | Compositions with vascular damaging activity | VEGFA, ACIN1, BCL2L13 | NOS1 2393/4885OTC 4770/4885DDAH1 2160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.